FDA Green-Lights Tirzepatide, Marketed as Zepbound, for Chronic Weight Management

JAMA. 2023 Dec 12;330(22):2143-2144. doi: 10.1001/jama.2023.24539.
No abstract available

Plain language summary

This Medical News article discusses the November 8 US Food and Drug Administration approval of the drug tirzepatide for chronic weight management in people with obesity or overweight with weight-related conditions.

MeSH terms

  • Anti-Obesity Agents* / therapeutic use
  • Chronic Disease
  • Disease Management
  • Humans
  • Obesity* / drug therapy
  • United States Food and Drug Administration / legislation & jurisprudence

Substances

  • tirzepatide
  • Anti-Obesity Agents